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LONG-TERM OUTCOME OF METHOTREXATE-FREE GVHD PROPHY-
LAXIS USING SIROLIMUS AND TACROLIMUS IN MATCHED RELATED
(MRD) AND UNRELATED DONOR (URD) PERIPHERAL BLOOD STEM
CELL TRANSPLANTATION (PBSCT)
Cutler, C.1, Li, S.1, Ho, V.1, Koreth, J.1, Alyea, E.1, Soiffer, R.J.1,
Antin, J.H.1 1Dana-Farber Cancer Institute, Boston, MA.
We report here our long-term results of sirolimus and tacrolimus
without methotrexate (Mtx) after MRD and URD PBSCT. Meth-
ods: Transplanted subjects had HLA-A, B, C and DR1 matched
MRD and URD donors. Conditioning consisted of cytoxan (1800
mg/m2 x 2) and TBI (14 Gy, 7 fractions). Tacrolimus (serum conc.
5-10 ng/mL) and sirolimus (serum conc. 3-12 ng/mL) were given
without Mtx as GVHD prophylaxis. G-CSF (5 g/kg/day) was ad-
ministered from day12 until neutrophil engraftment if needed. Re-
sults 53 MRD and 30 URD recipients were transplanted between
7/2002 and 8/2005. The median number of stem cells infused was
lower in MRD recipients (7.6 106 vs. 10.2 106 CD34 cells/kg,
p0.001), however, neutrophil engraftment was similar (14 vs. 13.5
days, p0.2). Platelet engraftment to 20 106/ml (12 vs. 12 days,
p0.13) and to 100106/ml (17.5 vs. 17 days, p0.32) was similar in
the two cohorts. The median time to hospital discharge was 19 days
in both groups (p0.95), with only 2 deaths (2.4%) prior to discharge.
Transplant-related toxicity included acute lung injury (IPS/DAH,
n1, 1.2%), hepatic veno-occlusive disease (VOD, n7, 8.4%) and
thrombotic microangiopathy (TMA, n6, 7.3%). The cumulative
incidence of grade II-IV acute GVHD was 20.5%, and was not
different between cohorts (18.9 vs. 23.3%, p0.78). There were only
3 cases of grade III-IV acute GVHD (2 MRD, 1 URD). In a com-
peting risk model (relapse/death as competing risk) the cumulative
incidence of chronic GVHD was 52.4% and was not different be-
tween groups (50.9 vs. 53.3%, p0.67). The median follow-up of all
surviving patients is 32.8 months from transplantation. Non-relapse
mortality at 30 and 100 days was 0% and 4.8%. Relapse-free survival
for the entire group was 72.3% and 68.5% at 1 and 2 years (MRD
71.7% and 66.0%; URD 73.3% at both times, log rank p0.5).
Overall survival at 1 and 2 years is 77.1% and 72.2% (MRD 77.4%
and 69.8%; URD 76.7% at both times, log-rank p0.58). Causes of
death include relapse(13), VOD(4), late pulmonary disease(3),
GVHD(2), infection and organ failure(2).ConclusionsWe conclude
that sirolimus in lieu of Mtx with tacrolimus for GVHD prophylaxis
is associated with low transplant-related toxicity, low rates of acute
Summary of Major Clinical Endpoints
Combined MRD URD p
Engraftment (days)
ANC > 500 14 14 13.5 0.2
Plt > 20 000 12 12 12 0.13
Plt > 100 000 18 17.5 17 0.32
1st Discharge 19 19 19 0.95
GVHD
Acute Gr. II-IV 20.5% 18.9% 23.3% 0.78
Acute Gr. III-IV 3.6% 3.6% 3.3% 0.99
Chronic 52.4% 50.9% 53.3% 0.67
Survival
30-day NRM 0 0 0 NA
100-day NRM 4.8% 5.7% 3.3%
1-yr RFS 72.3% 71.7% 73.3% 0.5
2-yr RFS 68.5% 66.0% 73.3%
1-yr OS 77.1% 77.4% 76.7% 0.58
2-yr OS 72.2% 69.8% 76.7%
ANC  Absolute Neutrophil Count; Plt  Platelet; NRM 
Non-Relapse Mortality; RFS  Relapse-Free Survival; OS 
Overall Survival
GVHD and excellent outcomes. Moreover, MRD and URD out-
comes appear to be equivalent, suggesting that the historical dis-
parity in outcomes between MRD and URD transplantation can be
abrogated with effective GVHD prophylaxis.
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HIGH RECIPIENT CD4CD25HI REGULATORY T-CELL LEVEL PRE-
TRANSPLANT IS ASSOCIATED WITH REDUCED OVERALL SURVIVAL
AFTER UNRELATED DONOR HEMATOPOYETIC STEM CELL TRANSPLAN-
TATION
Prieto-Hinojosa, A.1, Madrigal, J.A.1, Shaw, B.E.1, Mayor, N.P.1,
Marsh, S.G.E.1, Travers, P.1, Duarte, R.F.2 1The Anthony Nolan
Research Institute, London, United Kingdom; 2ICO - Hospital Duran i
Reynals, Barcelona, Spain.
CD4CD25hi T-cells (T-regs) have been identiﬁed as a naturally
occurring regulatory T-cell population. T-regs express FOXP3,
produce anti-inﬂammatory cytokines such as TGF upon activa-
tion, and are essential to maintain tolerance. Their potential im-
pact on the alloreactive phenomena and the outcome of HSCT in
humans, however, remains controversial. We have analyzed the
effect of pre-conditioning peripheral blood levels of CD4CD25hi
T-regs on the outcome of 89 adult patients undergoing HLA-
identical (10/10) unrelated donor (UD)-HSCT. Allografts were
T-cell depleted with Alemtuzumab, which has been described to
preserve T-regs from depletion. The percentage of T-regs pre-
transplant had no effect on transplant related mortality or the
incidence of acute GVHD, but higher T-regs levels did associate
with a higher risk or relapse (p0.027) and the incidence of
chronic GVHD (p0.033). Overall, patients with a higher propor-
tion of CD4CD25hi T-cells had a reduced overall survival fol-
lowing UD-HSCT (30% vs 65%, median follow up 1013 days;
p0.002).
Although T-regs have been clearly identiﬁed by the expression of
the transcription repressor factor FOXP3 in mice, FOXP3 expres-
sion in humans is not restricted to CD4CD25hi T-cells. In a
healthy donor control group (n30), CD4CD25hi-expression
correlated well with both, FOXP3 mRNA-expression (r0.649;
p0.001) and TGF production (r0.912; p0.001), as previ-
ously described for T-regs. In preconditioning patient samples,
CD4CD25hi-expression had also a strong correlation with TGF
regulatory cytokine production (r0.863; p0.001), as well as an
inverse correlation with TNF expression (r-0.458; p0.001), in
keeping with a true regulatory phenotype. FOXP3 mRNA-expres-
sion, however, correlated neither with the CD4CD25hi T-regs
phenotype (r0.280; p0.040), nor with TGF production
(r0.229; p0.156), and appeared not be an accurate marker for
regulatory T-cell function in this patient setting.
In summary, preconditioning patient percentage of T-regs may
inﬂuence the outcome of UD-HSCT through their effect on
alloresponses against the tumour and the host. Accurate identiﬁ-
cation of T-regs in these patients requires the analysis of their
immunophenotype and expression of functional markers. FOXP3
expression, however, may not identify true regulatory T-cell func-
tion in patients undergoing UD-HSCT.
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ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN HIV-
POSITIVE PATIENTS WITH MALIGNANT AND NON-MALIGNANT DISOR-
DERS: A REPORT FROM THE CENTER FOR INTERNATIONAL BLOOD
AND MARROW TRANSPLANT RESEARCH (CIBMTR)
Gupta, V.1, Tomblyn, M.1, Pederson, T.1, Thompson, J.1, Gress, R.1,
Storek, J.1, Burik, J.-A.1 van Horowitz, M.1, Keating, A.1 1CIBMTR
Infection and Immune Reconstitution Committee.
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